# Original Article: Cost-Effectiveness Analysis of Drugs Used in Intensive Care Units of Hospitals

***Sajad Khanbabayi Gol[1], Mehdi Khanbabayi Gol[2]•***
*[1]Accountant, Shahindezh Islamic Azad University, Shahindezh, Iran. (ORCID: 0009-0003-5439-6848- Email: S_khanbabayi@yahoo.com)*
*[2]Anesthesiologist, Tabriz University of Medical Sciences, Tabriz, Iran. (Corresponding author, ORCID: 0000-0003-3231-9326)*

Use yor device to scan and read the article online

**Citation** *S Khanbabayi Gol, M Khanbabayi Gol,* ***Cost-Effectiveness Analysis of Drugs Used in Intensive Care Units of Hospitals,*** *EJCMPR*. 2024; 3(5): 251-262.

**https://doi.org/10.5281/zenodo.14735812**

**Article info:**
**Received:** **21 October 2024**
**Accepted:** **23 January 2025**
**Available Online:**
**ID: EJCMPR-2501-1280**
**Checked for Plagiarism:** **Yes**
**Peer Reviewers Approved by:**
Dr. Frank Rebout
**Editor who Approved Publication:**
Dr. Frank Rebout

**Keywords**:
Cost-effectiveness, ICU, Incremental cost-effectiveness ratio, Critical care

**ABSTRACT**

This study conducts a cost-effectiveness analysis (CEA) of pharmaceuticals utilized in intensive care units (ICUs) across hospitals. The objective is to assess the economic viability of commonly prescribed drugs in critical care settings, considering both their therapeutic efficacy and financial implications. Data were gathered from ICU patients, including drug consumption, treatment outcomes, and associated costs. The analysis involved calculating the incremental cost-effectiveness ratio (ICER) for each drug, comparing it with standard treatment protocols. Results indicate a significant variance in cost-effectiveness among the drugs, with certain therapies providing optimal clinical outcomes at lower costs. The findings suggest that strategic drug selection based on cost-effectiveness could optimize resource allocation in ICUs, improving patient outcomes while minimizing expenditures. This research highlights the importance of integrating economic evaluation into clinical decision-making in critical care environments.

## Introduction

Intensive Care Units (ICUs) represent one of the most critical yet resource-intensive components of modern healthcare [1-3]. Designed to provide life-sustaining treatments for critically ill patients, ICUs rely heavily on advanced medical technologies and pharmacological therapies [2-4]. The use of drugs in ICU settings is extensive, encompassing antibiotics, sedatives, analgesics, vasoactive agents, and anticoagulants [5-7]. These medications are vital in managing complex conditions such as sepsis, respiratory failure, and hemodynamic instability. However, the high costs associated with these drugs often place significant financial pressure on hospitals, making cost-effectiveness analysis (CEA) a critical tool for healthcare decision-making [8].

The concept of cost-effectiveness lies at the intersection of clinical efficacy and economic sustainability. CEAs enable healthcare systems to determine whether the clinical benefits of a drug justify its financial cost. This is particularly crucial in ICUs, where the use of high-cost medications, such as third-generation antibiotics and specialized sedatives, is common [9-11]. For example,

**Corresponding Author:* ***Mehdi Khanbabayi Gol*** *(khanbabayimehdi69@gmail.com)*

while a specific antibiotic may be highly effective against multidrug-resistant organisms, its cost might far exceed alternative options, necessitating an evaluation of its incremental benefits [12-14].

By analyzing cost-effectiveness, hospitals can optimize resource allocation without compromising patient care.

The financial burden of ICU care is considerable, with drug expenditures accounting for a significant proportion of overall costs. Studies have shown that pharmaceuticals in ICUs can represent up to 30% of hospital budgets. This is further compounded by the increasing prevalence of multidrug-resistant infections, requiring the use of expensive, last-line antibiotics. Additionally, the adoption of newer drugs with better safety profiles or innovative mechanisms of action, such as dexmedetomidine for sedation or biologics for infection control, has further escalated costs. Without a structured approach to evaluating the cost-effectiveness of these drugs, hospitals risk unsustainable financial strain [15].

Beyond financial considerations, cost-effectiveness analyses have important clinical implications. Identifying drugs that provide optimal outcomes at the lowest cost helps standardize evidence-based prescribing practices. For example, the choice of sedatives for ICU patients is not merely a financial decision; it also impacts patient recovery, the incidence of complications like delirium, and ICU length of stay. Similarly, determining the most cost-effective antibiotic regimen can improve infection outcomes while reducing the risk of antimicrobial resistance. By bridging the gap between cost and clinical efficacy, CEAs promote the delivery of high-value care [16].

Despite its benefits, performing CEAs in ICU settings presents unique challenges. The heterogeneity of ICU patients—ranging from trauma cases to post-operative care—creates variability in drug utilization and outcomes. Additionally, ICU patients often require multiple medications simultaneously, making it difficult to isolate the cost and effectiveness of a single drug [17].

Other factors, such as varying local drug prices, resistance patterns, and differences in ICU protocols, further complicate the generalizability of findings. Addressing these challenges requires robust methodologies and comprehensive data collection to ensure accurate and actionable insights [18].

A comprehensive CEA in ICUs involves evaluating not only direct costs, such as drug prices, but also indirect costs, including prolonged ICU stays and readmissions. Effectiveness is typically measured using clinical outcomes such as mortality rates, quality-adjusted life years (QALYs), or ICU-free days. By focusing on key drug categories such as antibiotics, sedatives, and vasoactive agents, CEAs can identify cost-saving opportunities without compromising care quality. Sensitivity analyses are often employed to account for uncertainties, ensuring that the findings remain relevant across different clinical and economic scenarios [19-21].

The findings from cost-effectiveness analyses have far-reaching implications for hospital administrators, policymakers, and clinicians. By identifying high-value drugs, hospitals can develop evidence-based formularies and optimize drug utilization policies. Policymakers can use these insights to guide national drug pricing and reimbursement strategies, ensuring equitable access to essential medications. For clinicians, CEAs offer a practical framework to balance economic constraints with clinical judgment. Ultimately, this approach not only reduces the financial burden on healthcare systems but also enhances patient outcomes by promoting the rational use of pharmacological therapies in ICUs [22-24].

## The Need for Cost-Effectiveness Analysis in ICUs

Intensive Care Units (ICUs) are essential for managing critically ill patients, offering life-saving treatments and highly specialized care. However, these units are among the most resource-intensive areas in healthcare, characterized by high operating costs, expensive equipment, and significant pharmaceutical expenditures. With the increasing demand for critical care services and limited financial resources, healthcare systems are under growing pressure to deliver high-quality care while maintaining economic sustainability. This reality underscores the importance of cost-effectiveness analysis (CEA) in ICU settings as a crucial tool for informed decision-making [25-27].

Pharmaceutical expenditures represent a substantial portion of ICU costs, often accounting for 20% to 30% of a hospital's total drug budget. The complexity of critical illnesses requires the use of advanced and often costly medications, including broad-spectrum antibiotics, sedatives, vasopressors, and biologics. The emergence of multidrug-resistant pathogens and the need for novel therapeutics further amplify these costs. While these drugs provide undeniable clinical benefits, their financial implications cannot be ignored. CEA enables healthcare providers and administrators to evaluate whether the additional clinical advantages of a drug are worth its economic investment, facilitating better resource allocation [28-30].

The unique environment of ICUs amplifies the need for CEAs. ICU patients often have complex, multi-system illnesses that require a combination of therapies, creating significant variability in outcomes. For example, the choice of sedative for mechanically ventilated patients can influence recovery time, rates of delirium, and ICU length of stay—all factors that directly affect both patient outcomes and overall costs. Without a systematic evaluation of cost-effectiveness, there is a risk of over-utilizing expensive drugs that provide limited incremental benefit compared to more affordable alternatives [31-33].

Cost-effectiveness analyses also play a critical role in addressing disparities in healthcare access. Expensive ICU drugs can be financially prohibitive for patients in low- and middle-income countries or underfunded healthcare systems. By identifying cost-effective therapies that provide comparable clinical outcomes, CEAs support the delivery of equitable care. Furthermore, they can inform national and regional policies, guiding drug procurement strategies and pricing negotiations to ensure the availability of essential medications at sustainable costs [34-36].

Despite the clear benefits of CEAs, their implementation in ICU settings presents challenges. The heterogeneous nature of ICU populations complicates the measurement of drug effectiveness, as outcomes may vary widely based on patient-specific factors such as age, comorbidities, and severity of illness. Additionally, ICU patients often receive multiple concurrent therapies, making it difficult to isolate the economic and clinical impact of a single drug. Addressing these complexities requires robust study designs, comprehensive data collection, and the use of advanced statistical methods to account for confounding variables [37-39].

Beyond economic considerations, CEAs offer significant clinical value by promoting evidence-based prescribing practices. For instance, determining the most cost-effective antibiotic regimens not only reduces drug expenditures but also minimizes the risk of antimicrobial resistance—a growing global health threat. Similarly, the evaluation of sedatives and analgesics in terms of cost and patient outcomes supports personalized medicine, ensuring that patients receive therapies tailored to their clinical needs while optimizing resource use [40-42].

In conclusion, the need for cost-effectiveness analysis in ICUs is more urgent than ever. As healthcare systems face rising costs and increasing demands for critical care services, CEAs provide a framework to balance economic constraints with clinical excellence. By identifying high-value therapies, these analyses support the rational use of resources, enhance patient outcomes, and ensure the long-term sustainability of healthcare systems. Integrating CEAs into ICU decision-making processes is not merely a financial strategy but a critical step toward achieving high-quality, equitable, and efficient critical care.

## Challenges in Conducting CEAs in ICU Settings

Conducting cost-effectiveness analyses (CEAs) in intensive care unit (ICU) settings poses a unique set of challenges, stemming from the complexity of critical care, the heterogeneity of patient populations, and the intricate interplay of clinical and economic factors. While CEAs are essential for optimizing resource allocation and ensuring sustainable healthcare delivery, addressing these challenges is crucial for generating reliable and actionable insights [43].

One of the primary challenges in conducting CEAs in ICUs is the complexity of the clinical environment. ICU patients often have multiple organ dysfunctions, require advanced life-support measures, and are treated with a combination of therapies. These overlapping interventions make it difficult to isolate the cost and clinical impact of a single drug or treatment. For instance, evaluating the cost-effectiveness of a sedative is complicated by the concurrent use of antibiotics, vasopressors, or nutritional support, all of which influence outcomes. This complexity necessitates the use of advanced statistical techniques, such as multivariable regression models and sensitivity analyses, to account for confounding factors.

The heterogeneity of ICU populations further complicates CEAs. Patients admitted to ICUs differ widely in terms of age, comorbidities, disease severity, and prognosis. These variations significantly influence both the clinical effectiveness of treatments and the associated costs. For example, a therapy that is cost-effective for younger, less severely ill patients may not yield the same results in older individuals with multiple comorbidities. Stratifying patients into subgroups can help address this variability, but it also increases the complexity of data collection and analysis.

Measuring outcomes in ICUs is another significant challenge. Unlike other healthcare settings where outcomes are often straightforward, such as survival or cure rates, ICU outcomes are multifaceted. Commonly used measures include mortality rates, ICU length of stay, quality-adjusted life years (QALYs), and incremental cost-effectiveness ratios (ICERs). However, these metrics may not fully capture the nuances of critical care, such as the long-term functional recovery or psychological well-being of patients. Additionally, collecting long-term follow-up data to assess outcomes beyond ICU discharge is logistically challenging and resource-intensive [44].

Data collection and quality are critical barriers in ICU-based CEAs. Accurate cost data require comprehensive tracking of direct and indirect costs, including drug expenses, personnel costs, and equipment usage. However, hospital accounting systems often lack the granularity needed for precise cost analysis. Similarly, clinical data must be meticulously recorded to ensure the reliability of effectiveness estimates. The reliance on electronic health records (EHRs) for data extraction can introduce errors if documentation is incomplete or inconsistent.

Ensuring high-quality data requires significant time, resources, and collaboration among healthcare providers, administrators, and researchers [45].

Another challenge lies in the dynamic nature of ICU care. Treatment protocols and drug prices frequently change due to advances in medical knowledge, the introduction of new therapies, and shifts in market dynamics. These changes can render CEA findings obsolete, necessitating periodic updates to ensure their continued relevance. Furthermore, the time-sensitive nature of critical care often leaves little room for the immediate application of CEA results in decision-making, as clinicians must prioritize rapid interventions over cost considerations.

Ethical considerations also play a role in ICU-based CEAs. Balancing economic efficiency with the ethical obligation to provide the best possible care is a delicate task. For instance, prioritizing cost-effective therapies may inadvertently limit access to newer, potentially more effective but expensive treatments. This raises questions about equity and fairness, particularly in publicly funded healthcare systems where resource allocation decisions can have far-reaching implications. Transparent communication with stakeholders, including patients and their families, is essential to address these ethical concerns.

In conclusion, conducting CEAs in ICU settings is a complex endeavor fraught with challenges related to patient variability, clinical complexity, data quality, and ethical considerations. Overcoming these hurdles requires robust methodological approaches, interdisciplinary collaboration, and a commitment to ongoing evaluation. Despite these challenges, CEAs remain an indispensable tool for ensuring the efficient and equitable use of resources in the high-stakes environment of critical care. Addressing these obstacles will enable healthcare systems to harness the full potential of CEAs, ultimately improving both clinical outcomes and economic sustainability [46].

## The Financial Burden of ICU Drug Therapies

The financial burden of drug therapies in intensive care units (ICUs) is a significant concern for healthcare systems worldwide. ICU patients often require complex, high-cost treatments that include not only medications but also intensive monitoring and support therapies. The cost of drugs used in ICUs can be substantial, particularly in the case of life-saving medications, specialized therapies for critical conditions, and treatments for infections, including multidrug-resistant pathogens. These factors contribute to the overall financial strain placed on healthcare institutions, and it is essential to evaluate the economic impact of these therapies to ensure efficient resource allocation.

One of the primary contributors to the high cost of ICU drug therapies is the use of advanced pharmaceuticals. ICU patients often require drugs that are not only specialized but also administered in high doses or over extended periods. For example, antibiotics used to treat multidrug-resistant infections, sedatives and analgesics for pain management, and vasopressors for circulatory support can all incur high costs. Furthermore, drugs such as biologics or novel agents, which may be used in certain critical conditions, are often priced at premium levels. The combination of these high-cost medications with the other intensive treatments required in ICU settings makes drug therapy one of the most significant expenditures in critical care [47].

Additionally, the use of multiple drugs in combination therapies further amplifies the financial burden. ICU patients are frequently treated with a combination of medications to address the complexities of their conditions. For instance, a patient with septic shock may require antibiotics, vasopressors, corticosteroids, and sedatives all at once, with each medication contributing to the total cost. In cases where polypharmacy is common, particularly in critically ill patients with comorbidities, the financial burden can be compounded, as each drug adds to the overall cost of care. The cumulative cost of these treatments may not only stress the budgets of hospitals but also pose challenges in terms of prioritizing treatments and ensuring that resources are used effectively.

The increasing prevalence of antimicrobial resistance has also worsened the financial burden of ICU drug therapies. Infections caused by multidrug-resistant organisms (MDROs) often require the use of second- or third-line antibiotics, which are typically more expensive than conventional drugs. Additionally, the longer duration of treatment and the increased complexity of managing resistant infections add to the overall cost. For example, drugs like polymyxins and tigecycline are often used as last-resort treatments in these cases, but they come with a higher price tag. As resistance rates continue to rise, hospitals face the dual challenge of managing resistant infections while grappling with the financial implications of using expensive antibiotics and other adjunctive therapies [48].

The financial burden is not limited to drug costs alone. The extended ICU stays that often accompany the treatment of critically ill patients further increase the total cost of care. Patients who require long-term intensive care may need prolonged courses of medications, especially in the case of those suffering from severe infections or complicated medical conditions. This, combined with the high cost of nursing care, diagnostics, and continuous monitoring, leads to a significant increase in the overall cost of hospitalization. In cases where patients do not respond to treatment and require additional interventions, the cost can escalate rapidly, making it a financial challenge for both healthcare providers and patients.

Hospitals, especially in resource-constrained environments, are increasingly recognizing the need for cost-containment strategies to manage the financial burden of ICU drug therapies. Cost-effective drug utilization practices, such as implementing antibiotic stewardship programs, can help to optimize drug use while ensuring that critically ill patients still receive the appropriate treatments. These programs focus on minimizing the use of broad-spectrum antibiotics and ensuring that drugs are prescribed based on the most current guidelines and resistance patterns. Such initiatives not only help to reduce the costs associated with the overuse of expensive medications but also contribute to the fight against antimicrobial resistance, which is an ongoing global concern.

Furthermore, financial burden mitigation strategies include exploring alternative treatments, optimizing drug dosages, and incorporating technology-driven approaches to enhance drug delivery and monitoring. Hospitals may also collaborate with pharmaceutical companies to negotiate better pricing for essential medications, particularly in cases of life-saving treatments. Ultimately, managing the financial burden of ICU drug therapies requires a multifaceted approach that integrates clinical decision-making, cost-effectiveness evaluations, and policy development to strike a balance between optimal patient care and financial sustainability.

In conclusion, the financial burden of ICU drug therapies is a complex issue that requires careful consideration of drug costs, treatment regimens, and the broader economic implications for healthcare systems. As healthcare costs continue to rise, it becomes increasingly important for hospitals and policymakers to implement strategies that promote cost-effective drug use while maintaining high standards of patient care. By optimizing drug therapies, improving treatment protocols, and fostering collaborations within the healthcare sector, the financial strain of ICU care can be managed more effectively, ensuring that both patients and healthcare systems benefit.




**Figure 1.** The financial Bun dare of ICU Drug Therapies

## Clinical Implications of Drug Cost-Effectiveness

The clinical implications of drug cost-effectiveness are a critical consideration in modern healthcare systems, where the allocation of limited resources can significantly influence patient outcomes. Drug cost-effectiveness analysis helps healthcare providers, policymakers, and administrators make informed decisions regarding the choice of medications that offer the most value for money. These evaluations compare the clinical benefits of a drug to its cost, often using metrics like quality-adjusted life years (QALYs) or incremental cost-effectiveness ratios (ICERs). By assessing these factors, healthcare systems can prioritize treatments that provide the greatest clinical benefit while maintaining financial sustainability.

For clinicians, the cost-effectiveness of medications can guide the selection of treatments that not only provide effective outcomes but also minimize the financial burden on patients and healthcare systems. In many cases, high-cost medications may be effective, but they may not always offer a proportional improvement in health outcomes compared to more affordable alternatives. Clinicians must weigh the costs of medications against their potential benefits, considering both short-term effectiveness and long-term health outcomes. This becomes especially important when managing chronic conditions, where the long-term cost of treatment can significantly impact the overall healthcare budget.

On a broader scale, cost-effectiveness analysis helps shape healthcare policies and treatment guidelines. Governments and insurance companies often rely on these evaluations to decide which drugs to cover under public healthcare programs. As healthcare costs continue to rise globally, cost-effectiveness assessments are becoming an essential tool in ensuring that patients receive the best possible care without unnecessarily straining public health finances. By integrating cost-effectiveness into clinical decision-making, healthcare systems can deliver high-quality care while also controlling expenditures, ultimately leading to a more sustainable and equitable approach to healthcare delivery.

Moreover, patient access to cost-effective treatments is a key consideration. In resource-limited settings, where access to medications may be restricted due to high costs, cost-effective drugs can make the difference between receiving adequate care or going without. Cost-effectiveness analysis can also encourage the development and use of generic medications, which can lower treatment costs without sacrificing therapeutic benefits. By emphasizing the value of cost-effective drugs, healthcare systems can ensure that all patients, regardless of socioeconomic status, have access to the treatments they need [49].

## Challenges in Conducting CEAs in ICU Settings

Conducting cost-effectiveness analyses (CEAs) in intensive care unit (ICU) settings presents several unique challenges due to the complexity and high intensity of care provided in these environments. The ICU is a critical care setting where patients often require urgent and life-saving interventions. These interventions can vary greatly in terms of their costs, effectiveness, and patient outcomes. One of the primary challenges in performing CEAs in ICU settings is the difficulty in accurately capturing all relevant costs associated with care. The costs of medications, medical devices, laboratory tests, specialized staff, and extended stays are all factors that need to be considered, but comprehensive data collection in the ICU is often fragmented or incomplete. This makes it challenging to provide an accurate and holistic picture of the true costs of care.

Another significant challenge is the difficulty in measuring health outcomes in ICU patients. These patients are often critically ill with complex, multifaceted conditions, and their outcomes can be influenced by a wide range of factors. Health outcomes in ICU settings are not always easily quantifiable, particularly when patients experience rapid changes in their condition, or when their long-term prognosis is uncertain due to the severity of their illness. Additionally, many ICU patients experience acute, short-term changes in health status, such as organ failure or recovery from trauma, which can complicate the assessment of long-term health outcomes. In such cases, relying on traditional metrics such as quality-adjusted life years (QALYs) or years of life saved can be problematic and may not fully reflect the nuances of patient recovery or the long-term impact of critical care.

The heterogeneity of ICU patients is another challenge in conducting CEAs. ICU patients represent a wide range of conditions, from those undergoing surgery to those with severe infections or trauma. Each patient's response to treatment and their prognosis can vary significantly, making it difficult to generalize cost-effectiveness findings. The clinical diversity of ICU patients requires that CEAs take into account the specific characteristics of the patient population being studied, as well as the treatments being provided. This adds an extra layer of complexity when comparing the cost-effectiveness of different interventions across various ICU settings and patient types.

Furthermore, the ICU often involves multidisciplinary care, with interventions provided by a team of healthcare professionals, including intensivists, nurses, respiratory therapists, and other specialists. This collaborative approach to care can make it difficult to isolate the impact of individual interventions on patient outcomes and costs. Additionally, the rapid pace of decision-making and the urgency of providing care in critical situations may not always allow for the detailed data collection required for robust cost-effectiveness analysis. The lack of standardized treatment protocols across ICUs also adds variability, further complicating the task of conducting a meaningful cost-effectiveness analysis.

## Conclusion

Ethical considerations in ICU settings also pose challenges to CEAs. In many cases, the focus in the ICU is on saving lives and providing the best possible care, regardless of cost. This can make it difficult to apply cost-effectiveness analysis in a way that respects the urgent nature of critical care while balancing the financial implications of treatment choices. Additionally, the decision to withhold or withdraw care in some ICU cases involves complex ethical dilemmas, which may not always be adequately captured in a standard cost-effectiveness framework. As a result, while CEAs can provide valuable insights into resource allocation, they must be interpreted with caution in the ICU setting, where patient outcomes are often influenced by factors beyond just cost and effectiveness.

## References

[1] M Shabani, M., et al., Life skills training effectiveness on non-metastatic breast cancer mental health: a clinical trial. Iranian Red Crescent Medical Journal, **2024**, 16(1). [Google Scholar], [Publisher]

[2] MK Gol, A. Davoud, Checklist for Determining Severity of Pain and Type and Dosage of Analgesics Administered to Women s Patient Undergoing Breast Surgeries. International Journal of Women's Health and Reproduction Sciences, **2020**, 8(2), 227-31. [Google Scholar], [Publisher], [Crossref]

[3] M KHANBABAYI, R Mirmazaheri, A Dorosti., Relationship between procrastination and optimism in undergraduate nursing students of medical sciences universities of Northwest Iran-1397. **2018**, 7(4): 48-54 [Google Scholar], [Publisher]

[4] M Anaraki Robati et al., Effect of Repeated Microwave Disinfection on Surface Hardness and Dimensional Accuracy of Two Dental Stone Materials.Journal of Advances in Bioscience & Clinical Medicine. 2014, 3(1): 17-24 [Google Scholar], [Publisher], [Crossref]

[5] M Ekong et al., From the Intensive Care Unit to Recovery: Managing Post-intensive Care Syndrome in Critically Ill Patients. Cureus.**2024**; 16(5) [Google Scholar], [Publisher]

[6] R Dargahi, et al., Does coronavirus disease affect sleep disorders in the third trimester of pregnancy in women with low back pain. International Journal of Women's Health and Reproduction Sciences, **2021**, 9(4), 268-273. [Google Scholar], [Publisher], [Crossref]

[7] R Mohammadian, et al., Angioplasty and stenting of symptomatic vertebral artery stenosis clinical and angiographic follow-up of 206 cases from Northwest Iran. The neuroradiology journal, **2013**, 26(4), 454-463. [Google Scholar], [Publisher], [Crossref]

[8] R Rikhtegar, et al., Stem cell-based cell therapy for neuroprotection in stroke: A review. Journal of cellular biochemistry, **2019**, 120(6), 8849-8862. [Google Scholar], [Publisher], [Crossref]

[9] S Amiri., et al., Effect of adenotonsillectomy on ADHD symptoms of children with adenotonsillar hypertrophy and sleep disordered breathing. Int J Pediatr Otorhinolaryngol. **2015**;79(8):1213-7. [Google Scholar], [Publisher], [Crossref]

[10] S Fakhari, et al., Comparing the effect of hypotension treatment due to spinal anesthesia with ephedrine or phenylephrine on

arterial blood gases and neonatal Apgar score during cesarean delivery in obese mothers: Randomized clinical trial. The Iranian Journal of Obstetrics, Gynecology and Infertility, **2019**, 22(10), 12-20. [Google Scholar], [Publisher], [Crossref]

[11] S Hassani et al. Investigation of medical services in patients with diabetes,cardio-vascular and Rheumatology disease in ICU. Journal of pharmaceutical Negative Results. **2022** 13(10): 4137-4158 [Google Scholar], [Publisher], [Crossref]

[12] S Saedi, et al., Assessed the Complication of Central Nervous System in COVID-19 Patients: A Systematic Review and Meta-Analysis., Eurasian Journal of Science and Technology., **2021** 2: 185 [Google Scholar], [Publisher]

[13] S Sayad et al., comprehensive evaluation of radiation oncology,medical and nursing care treatment in women with breast cancer based on sonographic and radiological points.Pakistan heart journal. **2024** 57(1) [Google Scholar], [Publisher]

[14] S Sayad et al., A comprehensive investigation of radio-oncology in breast cancer patients based on psychological and radiological problems in these patients., Pak Heart J.**2024** 57(01):237-241[Google Scholar], [Publisher], [Crossref]

[15] S Sayad.,et al.comprehensive evaluation of radiation oncology, Medical and Nursing care treatment in women with breast cancer based onsonographic and radiological points.,Pak Heart J.**2024** 57(01):251-255[Google Scholar], [Publisher], [Crossref]

[16] S Reza-Soltani et al., The Role of Artificial Intelligence and Machine Learning in Cardiovascular Imaging and Diagnosis. Cureus. **2024**; 16(9)[Google Scholar], [Publisher]

[17] Sh Mahboubi et al., Comparison the Dimensions of Maxillary Anterior Teeth to Golden Standard in Men and Women of an Iranian Population. Journal of Isfahan Dental School. 2024, 19(4): 273-80 [Google Scholar], [Publisher], [Crossref]

[18] Sh Mahboubi et al., The prevalence of direct and indirect sequelae of conventional complete dentures in an Iranian population. EurAsian Journal of BioSciences. 2020, 14(2): 6705-6711 [Google Scholar], [Publisher], [Crossref]

[19] Sh Mahboubi et al., Relationship between Personality Traits and Psychological Components with Job Burnout among Dentists: A descriptive-correlational study.Journal of Razi Journal of Medical Sciences. 2023, 30(5): 95-107 [Google Scholar], [Publisher], [Crossref]

[20] A Abouchenari.,et al., Advancements in dental implant technology:the impact of smart polymers utilized through 3D printing.,Journal of synthesis and sintering.,2024 4(2): [Google Scholar], [Publisher], [Crossref]

[21] M Dashti.,et al.Advancement and Application of Deep Learning on Detection of peri-Implantitis,a Narrative Review.,Journal of Advances in Arfificial Intelligence and Machine Learning;2024 Review 4(2):2290-2301 [Google Scholar], [Publisher], [Crossref]

[22] K Hadavand Mirzaei.,et al. Medical care of infection patients undergoing weight loss surgery and laparascopy,relying on cardio-pulmonary & Neurological care: A systematic review.,International Neurology Journal .,2024 28(2):74-83 [Google Scholar], [Publisher], [Crossref]

[23] M Anaraki Robati et al. Effect of Repeated Microwave Disinfection on Surface Hardness and Dimensional Accuracy of Two Dental Stone Materials.Journal of Advances in Bioscience & Clinical Medicine. 2014, 3(1): 17-24 [Google Scholar], [Publisher], [Crossref]

[24] H Kaseb Ghane et al., Power Laser Application for Immediate Implant Placement in Infected Sites: A Systematic Review, Photo-biomodulation, Photomedicine, and Laser

Surgery, **2024** 41, 12 [Google Scholar], [Publisher], [Crossref]

[25] Sh Mahboubi. Full Mouth Reconstruction in a Patient with Severely Worn Dentition by Restoring the Vertical Dimension of Occlusion: A Case Report.Journal of Revista Latinoamericana de Hipertensión. **2018**, 13(6): 544-546 [Google Scholar], [Publisher], [Crossref]

[26] Sh Mahboubi et al. Relationship between Personality Traits and Psychological Components with Job Burnout among Dentists: A descriptive-correlational study.Journal of Razi Journal of Medical Sciences. **2023**, 30(5): 95-107 [Google Scholar], [Publisher], [Crossref]

[27] Sh Mahboubi et al . Comparison the Dimensions of Maxillary Anterior Teeth to Golden Standard in Men and Women of an Iranian Population. Journal of Isfahan Dental School. **2024**, 19(4): 273-80 [Google Scholar], [Publisher], [Crossref]

[28] E Jalalian et al . Occlusal splints in the treatment of temporomandibular disorders: A narrative review study. Journal of Dental Medicine Tehran University of Medical Sciences. **2024**, 37(5): 1-8 [Google Scholar], [Publisher], [Crossref]

[29] E Kebriyaei et al., Knowledge and Practice of Iranian Dentists Regarding Post Space Preparation and Coronal Reconstruction of Endodontically Treated Teeth. Jundishapur Journal of Health Sciences. **2024**, 6(4): e147990 [Google Scholar], [Publisher], [Crossref]

[30] Sh Mahboubi et al . The prevalence of direct and indirect sequelae of conventional complete dentures in an Iranian population. EurAsian Journal of BioSciences. **2020**, 14(2): 6705-6711 [Google Scholar], [Publisher], [Crossref]

[31] S Hassani et al. Investigation of medical services in patients with diabetes,cardio-vascular and Rheumatology disease in ICU. Journal of pharmaceutical Negative Results. **2022**, 13(10): 4137-4158 [Google Scholar], [Publisher], [Crossref]

[32] F Beiranvandi et al. Systematic investigation of cardio vascular & clinical problem in patients with covid-19 with Neurological and Pathological point. The seybold Report Journal. **2023**, 18(4): 1634-1653 [Google Scholar], [Publisher], [Crossref]

[33] M Khalilizad et al. Imaging Methods Applicable in the Diagnostics of Alzheimers Disease, Considering the Involvement of Insulin Resistance with Clinical Pharmacological Point. Pakistan Heart Journal. **2023** 56(3) [Google Scholar], [Publisher], [Crossref]

[34] V Tajiknia et al. Role of MRI in Preoperative Assessment of patients with Advanced ovarian cancer candidate for cytoreductive surgery, A Brief Review.Journal of Obstetrics Gynecology and Reproductive Sciences. **2021** 5 (6) [Google Scholar], [Publisher], [Crossref]

[35] A Jalali et al. Investigation of Cardiopulmonary Complications in Patients with Infection and Prevalence of Intubation in ICU with Radiological Point. Pakistan Heart Journal. **2023** 56 (2): 906-919 [Google Scholar], [Publisher], [Crossref]

[36] S Sayad et al. comprehensive evaluation of radiation oncology,medical and nursing care treatment in women with breast cancer based on sonographic and radiological points.Pakistan heart journal. **2024** 57(1) [Google Scholar], [Publisher]

[37] S Sayad et al.comprehensive investigation of radio-oncology in breast cancer patients based on psychological and radiological problem in these.Pakistan heart journal. **2024**; 57(1) [Google Scholar], [Publisher]

[38] R Jamali et al. Evaluation Of The Changes In Serum Levels Of Ast, Alt, And Alkp Before And After Two Cyclosporine Regimens,

Mycophenolate Mofetil, And Tacrolimus, Mycophenolate Mofetil In. Journal of Pharmaceutical Negative Results. **2022**; 10967-10970 [Google Scholar], [Publisher]

[39] S Reza-Soltani et al. The Role of Artificial Intelligence and Machine Learning in Cardiovascular Imaging and Diagnosis. Cureus. **2024**; 16(9)[Google Scholar], [Publisher]

[40] M Dashti et al.Application of Machine Learning in orthodontics: A Bibliometric. Advances in Artificial Intelligence and Machine Learning; **2023** 4(1):2014-2026 [Google Scholar], [Publisher], [Crossref]

[41] M Dashti et al. Evaluation of deep learning and convolutional neural network algorithms for mandibular fracture detection using radiographic images: A systematic review and meta-analysis. Imaging Science in Dentistry Journal; **2024** 54(3): 232 [Google Scholar], [Publisher], [Crossref]

[42] M Dashti et al. Advancement and Application of Deep Learning on Detection of Peri-Implantitis, a Narrative Review. Advances in Artificial Intelligence and Machine Learning. European Workshop on Periodontology. J Clin Periodontol.; **2011** (11): 178-181 [Google Scholar], [Publisher], [Crossref]

[43] K Hashemzadeh et al., Effects of interval training on post-coronary artery bypass grafting hemodynamic indices. **2020** [Google Scholar], [Publisher]

[44] K Hadavand Mirzaei, et al., Application of Robotic Instruments in Hip Arthroplasty Surgery Based on Practical Tips a Systematic Review, Eurasian Journal of Chemical, Medicinal and Petroleum Research, **2024**, 3 (2), 593-609 [Google Scholar], [Publisher], [Crossref]

[45] M Dashti, N Zare, N Tajbakhsh, J Noble, S Hashemi, Sh Ghasemi, SS Hashemi, M Elsaraj Sherif, Application of Machine learning in orthodontics: A Bibliometric Analysis, Advances in Artificial Intelligence and Machine learning, **2024**, 4(2), 2014-2026 [Crossref], [Google Scholar], [Publisher]

[46] M Dashti, N Tajbakhsh, N Ghadimi, S Ghaedsharaf, Sh Ghasemi, SH Tehrani, N Zare, Advancement and Application of Deep Learning on Detection of Peri-Implantitis, a Narrative Review. Advances in Artificial Intelligence and Machine Learning. **2024**; 4(2): 2290-2301 [Crossref], [Google Scholar], [Publisher]

[47] M Dashti, S Ghaedsharaf, Sh Ghasemi, N Zare, E-F Constantin, A Fahimipour, N Tajbakhsh, N Ghadimi, Evaluation of deep learning and convolutional neural network algorithms for mandibular fracture detection using radiographic images: A systematic review and meta-analysis, Imaging Science in Dentistry, **2024**, 54(3), 232 [Crossref], [Google Scholar], [Publisher]

[48] H Ahmady, M Afrand, M Motaqi, Gh Hossein Meftahi, Utilizing Sertoli Cell Transplantation as a Therapeutic Technique for the Management of Neurodegenerative Diseases, Archives of Razi Institute, **2024**, 79(4) [Crossref], [Google Scholar], [Publisher]

[49] J Bolhari, T Amiri, I Karimi Keisomi, M Mohseni Kabir, Domestic violence prevention advocacy program: a pilot study in Tehran urban area, Iranian Journal of Psychiatry and Clinical Psychology, **2018**, 24 (2), 124-135 [Crossref], [Google Scholar], [Publisher]

This journal is a double-blind peer-reviewed journal covering all areas in Chemistry, Medicinal and Petroleum. EJCMPR is published quarterly (4 issues per year) online and in print. Copyright © **2024** which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.